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TO THE EDITOR
Melanoma is among the most severe and
lethal forms of human skin cancer
(Mackie, 2006; Miller and Mihm Jr,
2006; Fecher et al., 2007; Gray-Schopfer
et al., 2007). For 2008, more than
110,000 new cases of melanoma (about
50,000 melanoma in situ (MIS) and
60,000 invasive melanomas) were esti-
mated with more than 8,000 deaths
(American Academy of Dermatology,
2008; Ries et al., 2008). To examine
genetic diversity, we studied metastatic
melanoma lesions from a patient with
xeroderma pigmentosum (XP). XP is a
rare genetic disease with defective DNA
repair and a more than 1000-fold in-
crease in melanoma frequency (Kraemer
et al., 1987, 1994; Ruenger et al., 2008).
The XP patient, (XP4BE), had no
blistering reaction to sunlight despite
living on a farm with unrestricted
exposure to sunlight. By 8 years of age
he had extensive freckling on his face
(Figure 1a). At the age of 9 years a large
warty tumor was excised from his nose.
He subsequently developed more than
100 cancers in sun-exposed skin, pri-
marily basal cell carcinomas and squa-
mous cell carcinomas, which were
treated with electrodessication and
curettage or surgical excision followed
by skin grafting (Figure 1b). At the age
of 23 years a primary malignant mela-
noma of the right post-auricular area
had been widely excised, and evidence
of spread was found in two of the
35 posterior cervical nodes.
XP4BE was admitted to the NIH
Clinical Center in 1969 at the age of 25
years (Robbins et al., 1974) and studied
in accordance with the NIH human
research guidelines then in eff-
ect. He was the first XP ‘‘variant’’ patient
recognized, a form of XP with normal
nucleotide excision repair (Robbins et al.,
1974). His cells were subsequently found
to have a defect in the error-prone
polymerase, polymerase eta (Johnson
et al., 1999; Masutani et al., 1999). At
admission, his neurological examination
was normal. In 1971, a melanoma
nodule was present on his scalp (Figure
1c). He had no beneficial response to
two courses of bis-choroethyl-nitrosourea
(BCNU), steroids, or radiation to the
brain and lumbar areas for treatment of
the metastatic melanoma. He died at the
age of 27 years in 1971. Autopsy
performed at NIH revealed thromboem-
boli with pulmonary infarctions, asper-
gillus pneumonia and cerebral abscess,
and metastatic melanoma involving his
brain, spinal cord, stomach, small bowel,
liver, gall bladder, adrenal glands, kid-
neys, lymph nodes, left testis, right lung,
pancreas, thyroid gland, and soft tissue of
the right thigh. The paraffin blocks from
this autopsy were recently retrieved,
sectioned, and stained. We do not have
tissue from the primary lesion, which was
removed before coming to NIH.
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We analyzed seven metastatic lesions
from this patient, the metastatic scalp
nodule obtained before BCNU treatment
(Figure 1c–e), and six lesions obtained at
autopsy (central nervous system (CNS)
 2, muscle, liver, kidney, and pancreas)
(Table 1) as well as normal tissue. Using
laser capture microdissection, we iso-
lated about 500 tumor or normal cells for
DNA analysis (Figure 1d and e) as
described previously (Wang et al.,
2009). To minimize formalin sequencing
artifacts (Williams et al., 1999), we
used more than 500 cells for analysis
and repeated the sequencing on inde-
pendent PCR products obtained from
adjacent regions of the tumor for several
tumors.
We studied the tumor suppressor
gene PTEN (phosphatase and tensin
homolog), which is one of the most
frequently mutated genes in human
cancer, including melanoma (Goel
et al., 2006; Baker, 2007) as well as
the NRAS and BRAF oncogenes that
have been reported to be mutated in
melanomas (Curtin et al., 2005). We
used sequencing techniques previously
described (Curtin et al., 2005; Wang
et al., 2009 and references therein).
Previously, we screened 59 primary
cutaneous melanomas from 8 other XP
patients and 56% had PTEN base
substitution mutations. There were 1–4
mutations in individual melanomas,
including MIS, the earliest stage of
melanoma (Wang et al., 2009).
Table 1 summarizes the pathological
and mutational features of all seven
metastatic melanoma lesions tested.
Samples from six (86%) of the
melanomas showed base substitution
A232G
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Figure 1. Clinical appearance, histology, and DNA sequencing of metastatic melanoma lesions in patient XP4BE. (a, b) Comparison of the face of patient
XP4BE at the ages of 8 and 27 years. By the age of 27, he had had surgery with grafting for many skin cancers (reproduced from Robbins et al. (1974)).
(c) Metastatic melanoma of the scalp before treatment with bis-choroethyl-nitrosourea (arrow). (d) Histology of metastatic melanoma lesion in scalp.
Atypical melanocytes are arranged in sheets and nests (arrow) (hematoxylin and eosin (H&E) staining, bar¼200 mm). (e) After capture of the melanoma cells,
the remaining tissue was inspected (arrow), and the transfer efficiency of about 500 captured cells was evaluated (H&E staining, bar¼ 200mm). (f) Sequencing
chromatograms for determination of PTEN mutations. The metastatic melanoma DNA shows a mutation compared with the normal tissue (arrow). LOH, loss of
heterozygosity. (Details of method are described in Wang et al. (2009)).
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mutations in the PTEN tumor suppressor
gene. No insertions or deletions were
observed. Fifteen base substitution mu-
tations were detected and 14 of these
were different from each other. There
was 1 nonsense mutation (Gln245X),
12 missense mutations, and 2 synon-
ymous mutations that did not alter the
amino-acid sequence. Individual meta-
static lesions showed marked genetic
diversity with 1–4 different PTEN base
substitution mutations: the liver lesion
had one mutation; a CNS and a skeletal
muscle metastasis each had two muta-
tions; kidney and pancreas metastases
each had three mutations; and the
metastatic melanoma lesion on the
scalp had four different mutations.
Thirteen (87%) of the mutations were
present at dipyrimidine sites, a feature
of UV-induced mutations (Wang et al.,
2009). Loss of heterozygosity was found
in two of the metastatic melanomas that
also had PTEN missense mutations.
A Thr167Ala missense mutation was
reported previously in an astrocytoma
(Raffel et al., 1999). The missense
mutations were located in the dual-
specificity protein phosphatase domain
(amino acids 25–179) as well as in the
calcium/lipid binding region (amino
acids 190–347).
Two of four (50%) of the metastatic
lesions tested had NRAS base substitu-
tion mutations. One mutation in NRAS
was found in the kidney metastasis and
two NRAS mutations were found in the
pancreas metastasis. However, these
three NRAS mutations were all synon-
ymous. None of the five metastatic
lesions tested had BRAF base substitu-
tion mutations. The low frequency of
mutations in NRAS and BRAF contrasts
with the higher frequency of mutations
in the PTEN gene obtained from the
same samples and suggests that PTEN
mutations were not the result of for-
malin artifacts that would be expec-
ted to similarly affect all genes
(Williams et al., 1999). Thus, mutations
in the NRAS and BRAF oncogenes did
not appear to have a major role in
metastasis of melanomas in this XP
patient.
Patient XP4BE presented with meta-
static lesions. In our study of early
melanomas in other XP patients (Wang
et al., 2009), we found the UV type
mutations, gGc131gAc and aGg164aAg,
in MIS lesions. These same mutations
were also present in three of the meta-
static lesions (liver, CNS, and kidney)
(Table 1) and might have been present in
the primary melanoma(s) in XP4BE.
These mutations result in amino-acid
alterations (Gly44Asp and Arg55Lys) in
the protein phosphatase domain of PTEN
and may represent persistent UV-in-
duced genetic alterations associated with
metastasis.
Surprisingly, there was no single
mutation present in all of the metastatic
lesions, as would be expected if all of
the metastases arose from a single
primary melanoma (Wang et al.,
2006; Sabatino et al., 2008). Multiple
tumor samples from the same patient
had different mutations, indicating the
Table 1. Mutations in PTEN, NRAS, and BRAF in metastatic melanoma lesions from patient XP4BE
PTEN NRAS BRAF
Metastatic
lesion no.
Metastatic
melanoma site Mutation
UV type
mutation?1 LOH?2
Amino-acid
change Mutation
Amino-acid
change Mutation
1 Liver gGc131gAc3 +  Gly44Asp3 Normal Normal Normal
2 CNS-1 aGg164aAg3 + + Arg55Lys3 NT4 NT Normal
2 CNS-1 tAt521tGt   Tyr174Cys
3 Skeletal muscle tCa733tTa +  Gln245X NT NT NT
3 Skeletal muscle gTc882gCc +  Ser294Ser5
4 Kidney aGg164aAg3 +  Arg55Lys3 aTc99aCc Asp33Asp5 NT
4 Kidney aAc499aGc +  Thr167Ala6
4 Kidney aGg663aTg + + Lys221Asn
5 Pancreas tAa162tGa +  Val54Val5 aAt93aGt Glu31Glu5 Normal
5 Pancreas gGa494gTa +  Gly165Val cCa105cTa Thr35Thr5
5 Pancreas tTa562tCa +  Tyr188His
6 Scalp gAt152gGt +  Asp51Gly NT NT Normal
6 Scalp cAc232cGc   Thr78Ala
6 Scalp aAg548aGg +  Lys183Arg
6 Scalp gTt583gCt +  Phe195Leu
7 CNS-2 Normal Normal Normal Normal Normal
1+, Dipyrimidine; , not dypyrimidine.
2+, Loss of heterozygosity; , no loss of heterozygosity.
3Mutation reported in in situ melanoma in XP patients (Wang et al., 2009).
4NT, not tested.
5Synonymous mutation (no amino-acid change).
6Mutation reported in an astrocytoma (Raffel et al., 1999).
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presence of different clonal populations
of tumor cells in different metastatic
lesions. Independent PCR amplification
of laser capture microdissected tumor
tissue from adjacent areas of tumors 1,
2, and 4 revealed the identical muta-
tions in PTEN exon 2 as shown in Table
1, with no new mutations found, which
is evidence that these mutations were
not formalin artifacts (Williams et al.,
1999). In addition, normal PTEN seq-
uence was obtained for exons 4, 6,
7, and 8 for tumors 1–6, suggesting
that there were local sequence varia-
tions in these metastatic melanomas.
These metastatic lesions with different
PTEN mutations might have arisen
from different primary melanomas.
The high frequency of UV type muta-
tions in these metastatic lesions (87
vs 54% expected (Wang et al., 2009))
is consistent with their origin from
sunlight-induced primary melanomas.
Alternatively, alterations in other
gene(s) might have induced the metas-
tases (Wang et al., 2006; Sabatino et al.,
2008). As in the primary melanomas
(Wang et al., 2009), the finding of
multiple PTEN mutations in metastatic
lesions indicates that there is a marked
genetic diversity in these tumors, per-
haps reflecting the hypermutability of
XP variant cells (Waters et al., 1993;
Stary et al., 2003; Wang et al., 2007). A
similar genetic heterogeneity of meta-
static melanomas from non-XP patients
was reported based on the studies of
loss of heterozygosity and X-chromo-
some inactivation (Katona et al., 2007).
This genetic diversity may affect mela-
noma development, progression toward
metastasis, and response to therapy.
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